Marlabs, a leading technology solutions provider, is expecting a significant boost in its data and artificial intelligence (AI) business in the coming years. The company’s CEO, Collins, has revealed ambitious plans to grow this segment by a remarkable 50% within the next 2-3 years.
Collins emphasized the importance of the life sciences and healthcare sectors for Marlabs, highlighting ongoing projects with major clients in these industries. One notable initiative involves the development of AI solutions for clinical trials and improving operational efficiency at one of the world’s largest hospital chains.
The company anticipates a positive impact from global trends in the third quarter of the financial year 2025, with expectations of substantial growth in this period. Collins attributed this growth not only to economic factors but also to Marlabs’ strategic shift towards data AI and product engineering. The recent acquisition of Onebridge is expected to play a crucial role in driving synergies, expanding capabilities, and fueling further growth for the company.
